You are in: eMedicine Specialties > Ophthalmology > CORNEA Corneal AbrasionArticle Last Updated: Mar 26, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Arun Verma, MD, Senior Consultant, Department of Ophthalmology, Dr Daljit Singh Eye Hospital, India Editors: Kilbourn Gordon III, MD, FACEP, Urgent Care Physician, Primary Medical, Huntington Walk-In and Greenwich Convenient Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College; Co-Chairman of the Cornea Service, Co-Chairman of Refractive Surgery Department, Wills Eye Hospital; Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri; Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences Author and Editor Disclosure Synonyms and related keywords: superficial corneal injuries, superficial corneal defects, epithelial defects, transient corneal erosions, ocular abrasion, ocular injuries, corneal ulcers, foreign body, corneal injury, scraped cornea, scratched cornea, eye scratch, something in the eye, foreign body sensation, eye pain, corneal epithelial defect, photophobia, keratitis INTRODUCTIONBackgroundCorneal abrasion is probably the most common eye injury and perhaps one of the most neglected. It occurs because of a disruption in the integrity of the corneal epithelium or because the corneal surface scraped away or denuded as a result of physical external forces. Corneal epithelial abrasions can be small or large, but they usually heal without serious sequelae. However, deep corneal involvement may result in facet formation in the epithelium or scar formation in the stroma. Abrasions of the corneal epithelium are common and frequently missed. Because they heal rapidly, they are considered of little consequence. Corneal abrasions occur in any situation that causes epithelial compromise. Examples include corneal or epithelial disease (eg, dry eye), superficial corneal injury or ocular injuries (eg, those due to foreign bodies), and contact lens wear (eg, daily disposable soft lenses, extended-wear soft lenses, gas permeable lenses, hard polymethylmethacrylate lenses). Spontaneous corneal abrasions may be associated with map-dot-fingerprint dystrophy or recurrent corneal erosion syndrome. Corneal abrasions can be classified as traumatic, foreign body related, contact lens related, or spontaneous. Spontaneous corneal abrasions are also known as recurrent erosions. A traumatic corneal abrasion is the classic corneal abrasion in which mechanical trauma to the eye results in a defect in the epithelial surface. Traumatic corneal abrasions are often caused by fingernails, paws, pieces of paper or cardboard, makeup applicators, hand tools, branches, and leaves. Traumatic abrasions can also be caused by a foreign body that has lodged under the lid.Foreign body–related abrasions are defects in the corneal epithelium that are left behind after the removal of or spontaneous dislodgement of a corneal foreign body. Foreign body abrasions are typically caused by pieces of rust, wood, glass, plastic, fiberglass, or vegetable material that have become embedded in the cornea. Contact lens–related abrasions are defects in the corneal epithelium that are left behind after the removal of an over-worn, improperly fitting, or improperly cleaned contact lens. These eyes have suffered a mechanical insult that is not from external trauma but rather from a foreign body that is associated with specific pathogens. Spontaneous defects in the corneal epithelium may occur with no immediate antecedent injury or foreign body. Eyes that have suffered a previous traumatic abrasion or eyes that have an underlying defect in the corneal epithelium are prone to this problem. PathophysiologyAnatomy and physiology of corneal abrasion Abrasion is a defect in the surface of the cornea that is limited to the epithelial layers and that does not penetrate the Bowman membrane. In some cases, the bulbar conjunctiva is also involved. Corneal abrasion results from physical or chemical trauma. Severe corneal injuries can also involve the deeper, thicker stromal layer; in this situation, the term corneal ulcer may be used. The conjunctival response to corneal wounding has been known since Mann first observed that peripheral corneal abrasions heal by the sliding of limbal cells to cover the epithelial defect.1 This response is split into 2 phases: (1) the response of the limbal epithelium, which is the source of the corneal epithelial stem cells, and (2) the response of the conjunctival epithelium itself. Under normal circumstances, the limbal epithelium acts as a barrier and exerts an inhibitory growth pressure that prevents the migration of conjunctival epithelial cells onto the cornea. Like the rest of the surface of the body, the conjunctiva and the cornea are in a constant state of turnover. Corneal epithelial cells are continuously shed into the tear pool, and they are simultaneously replenished by cells moving centrally from the limbus and anteriorly from the basal layer of the epithelium. Movement from the basal to superficial layers is relatively rapid, requiring 7-10 days; however, movement from the limbus to the center of the cornea is slow and may require months. This normal physiologic process is exaggerated in the case of a corneal abrasion. During corneal healing of a lesion, corneal epithelial cells become flattened, they spread, and they move across the defect until they cover it completely. Cell proliferation, which is independent of cell migration, begins approximately 24 hours after injury. Stem cells from the limbus also respond by proliferating to give rise to daughter cells called transient amplifying cells. These cells migrate to heal the corneal defect and proliferate to replenish the wounded area. The observation of limbal pigment migrating onto the clear cornea provided additional evidence of this process. The concept that the limbal cells form a barrier to conjunctival cells was supported further by the observation that rabbit eyes treated for 120 seconds with N-heptanal, which removed the corneal and conjunctival epithelium but left the limbal basal cells intact, healed with the corneal epithelium and had unvascularized corneas. However, when the entire limbal zone was surgically removed along with N-heptanal treatment, corneal vascularization and conjunctivalization was observed. Demonstration of the centripetal migration of limbal cells (marked by India ink) provided more direct evidence of this concept. These cells migrate in masses as a continuous, coherent sheet, with most cells retaining their positions relative to each other, much like the movement of a herd of cattle. Rearrangement of intracellular actin filaments plays a role in movement. Cell migration can be inhibited by blocking polymerization of actin, indicating that actin filaments actively participate in the mechanism of cell motion. Some authors believe that conjunctival and limbal epithelial cells may contribute to the regeneration of corneal epithelium. Marked proliferative responses in the conjunctiva after a central corneal epithelium abrasion have been described. Why the conjunctival epithelium should proliferate in response to a central corneal wound is unknown. One possibility is that the proliferation replenishes the number of goblet cells, which decreases by up to 50% after corneal wounding. However, proliferation occurs at high levels in the bulbar conjunctiva, which contains few if any goblet cells. The apparent decrease in cell number is more likely the result of mucin secretion rather than actual loss of goblet cells. Alternately, conjunctival cells may migrate into the limbus or cornea to help replenish the wound area. No firm data suggest that conjunctival epithelium migrates onto the corneal surface in the presence of intact limbal epithelium. Last, healing of the corneal epithelial wound is not complete until the newly regenerated epithelium has firmly anchored itself to the underlying connective tissue. Permanent anchoring units are not formed until the wound defect is covered completely. Epithelial cells migrate rapidly and develop strong, permanent adhesions within 1 week when the basement membrane is regularly formed and released during the cell migration process. Although transient attachments are regularly formed and released during the cell migration process, formation of normal adhesions takes 6 weeks, according to Dua et al.2 Tiny buds of corneal epithelium are present along the contact line between the normal corneal epithelium and the migrating conjunctival epithelium. These buds arise from the corneal epithelium, and normal corneal epithelium appears to replace the conjunctival epithelium by gradually pushing it toward the limbus. The magnitude and extent of both the conjunctival and corneal regenerative responses to a corneal abrasion are correlated with the size of the wound. Large erosions were reported to induce a pronounced response in the rate of epithelial cell migration and mitosis at the limbus. Insults caused by chemical injuries, Stevens-Johnson syndrome, contact lens–induced keratopathy, and aniridia result in limbal damage. These insults cause delayed healing of the cornea, recurrent epithelial erosions, corneal vascularizations, and conjunctival epithelial ingrowth. Role of the epithelial defect A long-standing clinical observation is that corneal abrasions and bacterial corneal infections do not occur in patients with an intact, healthy epithelium. Bacterial keratitis and abrasions develop in 1 of 3 types of patients: (1) those with trauma to the cornea; (2) those with epithelial defects due to intrinsic disease (eg, dry eye, exposure keratitis, neurotrophic keratitis, postinfectious persistent epithelial defects); and (3) those who wear contact lenses, especially extended-wear hydrophilic lenses. The common feature among the 3 groups is a defect in the corneal epithelium to which the bacteria must adhere to start the infection. Mechanisms underlying the development of epithelial defects in the first 2 groups are self-evident. In the third group, contact lenses may lead to epithelial injury in different ways. The cornea can be injured by insertion or removal of the lens, by trauma from defects in or deposits on the lens, by lens-induced hypoxia, or by chemical toxicity from contact-lens disinfectants. Defects in the epithelium need not be full thickness. Overnight wearing of soft lenses, which do provide inadequate oxygen transmissibility to prevent hypoxia, causes superficial desquamation of epithelium and increases the propensity for abrasions. Corneal swelling induced by overnight wearing of contact lenses is the most important factor. The cornea normally swells 2-4% during sleep. With a contact lens, overnight swelling is increased to an average of 15%, and gross stromal edema can be present on awakening. In some patients, induced corneal swelling can be sufficient to cause bullae; these can rupture, leading to epithelial defects. FrequencyUnited StatesCorneal abrasions are the most common eye injuries and especially prevalent among people who wear contact lenses. Although corneal abrasions account for about 10% of eye-related emergency visits, the estimated incidence varies by population and depends on how they are defined and the activities involved in the mechanism of injury. A sampling of diagnoses in the offices of family practice clinicians, internists, and pediatricians in the United States in 1985 found that eye complaints constituted 2% of all patient visits; traumatic conditions and foreign bodies were the reason for 8% of these visits. Workplace eye injuries cause significant yet avoidable (with protective eyewear) morbidity and lost productivity. A study of eye injuries in a major US automotive corporation found an annual incidence of 15 eye injuries per 1000 employees. The eye injuries comprised 6% of total injuries, and corneal foreign bodies and abrasions were 87% of eye injuries. One third of eye injuries resulted in the inability of workers to resume normal duties for at least 1 day. In another report, most patients with corneal foreign bodies did not take more than 1 day off work, and up to 30% sought treatment outside of working hours to avoid lost time from work. See also the Mortality/Morbidity section. InternationalThe incidence of nonpenetrating injuries to the eye, which includes corneal abrasions, is 1.57% per year. Mortality/MorbidityAlthough corneal abrasions are often regarded as inconsequential (especially by patients who are poor), these injuries can cause significant ocular and visual morbidity.
RaceRates of corneal abrasion are equal in all races. SexMore males than females are treated for corneal abrasions. AgeThe incidence is increased among those of working age because younger people are more active than older people; however, people of all ages can have a corneal abrasion. CLINICALHistoryThe patient's history typically includes trauma to the eye due to either a foreign object or a contact lens. In general, symptoms of a corneal abrasion include foreign body sensation, pain, and photophobia. Symptoms range from mild foreign body sensation in cases of small abrasions to severe pain in large abrasions. Symptoms typically begin instantly after trauma occurs and can last minutes to days depending on the size of the abrasion. Other symptoms include photophobia, especially if secondary traumatic iritis is present. Excessive tearing may occur. Conjunctival injection and eyelid swelling may be present.
PhysicalIn some cases, the findings are missed because of the insignificant nature of the causative agent or because of insignificant discomfort; however, the majority of patients with corneal abrasions have the same clinical presentation. The corneal epithelium is richly innervated with sensory pain fibers from the trigeminal nerve. Thus, patients typically complain of excruciating eye pain and an inability to open the eye due to foreign body sensation. Often, patients are too uncomfortable to work, drive, or read, and the pain frequently precludes sleep. Multiple attempts by the patient to "wash out" the eye can further disrupt the epithelial surface.
Causes
DIFFERENTIALSBlepharitis, Adult Conjunctivitis, Bacterial Conjunctivitis, Viral Corneal Erosion, Recurrent Corneal Foreign Body Dry Eye Syndrome Dystrophy, Map-dot-fingerprint Entropion Glaucoma, Angle Closure, Acute Herpes Simplex Keratitis, Bacterial Keratoconjunctivitis, Sicca Keratopathy, Neurotrophic Laceration, Corneoscleral Trichiasis Ulcer, Corneal Uveitis, Anterior, Granulomatous Uveitis, Anterior, Nongranulomatous
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Ofloxacin (Ocuflox) |
|---|---|
| Description | Pyridine carboxylic acid derivative with broad-spectrum bactericidal effect. Inhibits bacterial growth by inhibiting DNA gyrase. Indicated for superficial ocular infections of conjunctiva or cornea due to susceptible microorganisms. |
| Adult Dose | 1 gtt in affected eye qid for 1 wk |
| Pediatric Dose | <1 year: Not established >1 year: 1-2 gtt in affected eye q2-4h for first 2 d; then qid for 5 d |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | No response after 2-3 d may indicate resistant organism or another causative agent |
| Drug Name | Polymyxin B/trimethoprim (Polytrim) |
|---|---|
| Description | For ocular infection of cornea or conjunctiva caused by susceptible microorganisms. Solution (polymyxin/trimethoprim) and ointment (polymyxin/bacitracin). |
| Adult Dose | Solution: 1-2 gtt in affected eye q4h while awake Ointment: Apply 0.5-inch ribbon into conjunctival sac qid and/or qhs |
| Pediatric Dose | <2 months: Not established >2 months: Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, fungal, and mycobacterial eye infections; deep ocular infections or those likely to become systemic |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Prolonged or repeated use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organism |
| Drug Name | Ciprofloxacin (Cipro, Ciloxan); Norfloxacin (Chibroxin) |
|---|---|
| Description | Ciprofloxacin has activity against Pseudomonas and Streptococcus species, MRSA, Staphylococcus epidermidis, and most gram-negative organisms; no activity against anaerobes. Norfloxacin has activity against susceptible gram-negative and gram-positive bacteria. Antibiotics in this class inhibit bacterial DNA synthesis and thus growth by inhibiting DNA gyrase. |
| Adult Dose | Ciprofloxacin or norfloxacin: Drops: 1 gtt qid for 7 d; for suspected corneal ulcers, 1-2 gtt qh for first 24 h then qid for 7 d Ointment: 0.5-in qhs to q6h depending on need Oral ciprofloxacin: 250-500 mg PO bid for 7-14 d |
| Pediatric Dose | Ciprofloxacin or norfloxacin: Drops: <1 year: Not established >1 year: Administer as in adults Ointment: Administer as in adults Oral: <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, mycobacterial, and fungal eye infections; coadministration with steroid combination after uncomplicated removal of a foreign body from cornea; deep ocular infections likely to become systemic |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after dose; cimetidine may interfere with metabolism; reduces therapeutic effects of phenytoin; probenecid may increase serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT); no drug interactions reported for ophthalmic dosage forms |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, periodically evaluate organ (eg, renal, hepatic, hematopoietic) function; adjust dose in renal impairment; superinfections may occur with prolonged or repeated antibiotic therapy; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Bacitracin, neomycin, and polymyxin B (triple antibiotic, Septa Topical Ointment) |
|---|---|
| Description | Bacitracin prevents transfer of mucopeptides into growing cell wall, inhibiting bacterial growth. Neomycin used to treat minor infections; inhibits bacterial protein synthesis and growth. Polymyxin B disrupts bacterial cytoplasmic membrane, permitting leakage of intracellular constituents, inhibiting bacterial growth. |
| Adult Dose | Apply 1-4 times/d to affected areas and cover with sterile bandages as needed |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; epithelial herpes simplex keratitis; mycobacterial and fungal infections |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in treating extensive burns (>20% body surface area), as absorption of neomycin possible and may cause nephrotoxicity and ototoxicity; prolonged use may result in overgrowth of nonsusceptible organisms |
| Drug Name | Erythromycin (E-Mycin) |
|---|---|
| Description | Indicated for infections caused by susceptible strains of microorganisms and for prevention of corneal and conjunctival infections. |
| Adult Dose | Apply 0.5-inch (1.25-cm) ribbon 2-8 times/d depending on severity of infection |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; viral, mycobacterial, fungal eye infections; coadministration with steroid combination after uncomplicated removal of foreign body from cornea; ocular infections that may become systemic |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and may lead to a secondary infection (take appropriate measures if superinfection occurs) |
| Drug Name | Sulfacetamide sodium 10% (Sulamyd, Bleph-10) |
|---|---|
| Description | Interferes with bacterial growth by inhibiting bacterial folic acid synthesis by competitively antagonizing PABA. Solution, ointment, and lotion. |
| Adult Dose | Solution: 1-3 gtt q2-3h in affected eye while awake, less frequently at night Ointment: Apply 0.5-inch ribbon 1-4 times/d into conjunctival sac |
| Pediatric Dose | <2 months: Not established >2 months: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Effects decreased when used concurrently with gentamicin |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in severely dry eye; ointment may retard corneal epithelial healing |
| Drug Name | Tobramycin (Tobrex) |
|---|---|
| Description | Aminoglycoside that interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, causing a defective bacterial cell membrane. Solution, ointment, and lotion. |
| Adult Dose | Solution: 1-2 gtt q4h in the affected eye while awake, less frequently at night Severe infections: 2 gtt q30-60min for the first 24 h, followed by less frequent intervals Ointment: Apply 0.5-inch ribbon bid/tid into conjunctival sac Severe infections: Apply q3-4h |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; mycobacterial, viral, and fungal infections of the eye; steroid combinations after uncomplicated removal of a foreign body from cornea should also avoid using this product |
| Interactions | Effects decrease when used concurrently with gentamicin |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Do not use in deep-seated ocular infections or in those that may become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Gentamicin (Ocumycin, Genoptic) |
|---|---|
| Description | Aminoglycoside antibiotic to cover gram-negative bacteria. |
| Adult Dose | Solution: 1-2 gtt q4h in affected eye while awake, less frequently at night Severe infections: 2 gtt q30-60min for the first 24 h, then less frequently |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; mycobacterial, viral, and fungal eye infections; coadministration with steroid combinations after uncomplicated removal of a foreign body from cornea; ocular infections that may become systemic |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and lead to secondary infection |
These drugs are used in large abrasions. Specific agents such as cyclopentolate or atropine or even homatropine drops or ointments are useful adjuncts.
| Drug Name | Scopolamine (Isopto Hyoscine Ophthalmic, Isopto) |
|---|---|
| Description | Blocks action of acetylcholine at parasympathetic sites in smooth muscle, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). |
| Adult Dose | 1-2 gtt into affected eye 1-4 times/d; compress lacrimal sac with digital pressure for 1-3 min after instillation to avoid excessive systemic absorption |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; primary or initial stages of glaucoma |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Possible drowsiness, blurred vision, or sensitivity to light (due to dilated pupils); caution while driving or performing tasks requiring alertness, coordination, or physical dexterity |
| Drug Name | Cyclopentolate HCl 1% (Cyclogyl, AK-Pentolate, I-Pentolate) |
|---|---|
| Description | DOC in the treatment of cornea abrasions. Prevents the muscle of ciliary body and sphincter muscle of the iris from responding to cholinergic stimulation, causing mydriasis and cycloplegia. Induces mydriasis in 30-60 min and cycloplegia in 25-75 min; effects up to 24 h. |
| Adult Dose | 1 gtt of 1% solution usually adequate to induce cycloplegia; repeat in 5-10 min prn |
| Pediatric Dose | <1 year: 1 gtt of 0.5% into each eye before examination; repeat q5-10 min prn >1 year: Instill 1 gtt of 0.5%, 1%, or 2% solution to induce cycloplegia; repeat in 5-10 min prn |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
| Interactions | Decreases effects of carbachol and cholinesterase inhibitors |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Exercise caution in patients (eg, elderly) where increased intraocular pressure may be present; can cause toxic anticholinergic systemic adverse effects (common in children, especially infants), but incidence rare when used sparingly; compressing lacrimal sac by digital pressure for 1-3 min, following application, may minimize systemic absorption |
| Drug Name | Atropine (Isopto, Atropair, Atropisol) |
|---|---|
| Description | Acts at parasympathetic sites in smooth muscle to block response of sphincter muscle of iris and muscle of ciliary body to acetylcholine, causing mydriasis and cycloplegia. Concurrent phenylephrine (2.5% or 10% solution) may prevent formation of synechiae by producing wide dilation of pupil. Induces mydriasis in 10-30 min and cycloplegia in 30-90 min; effects up to 48 h. |
| Adult Dose | Atropine solution (1%): 1-2 gtt 1-4 times/d; compress lacrimal sac with digital pressure for 1-3 min after instillation to avoid excessive systemic absorption Ointment: Apply 0.5-inch ribbon in conjunctival sac tid Homatropine solution (2%): 1-2 gtt of 2% or 1 gtt of 5% solution to induce cycloplegia; repeat in 15-20 min prn; compress lacrimal sac with digital pressure for 1-3 min after instillation to avoid excessive systemic absorption For prolonged cycloplegia: 1-2 gtt up to q3-4h; individuals with heavily pigmented irides may require larger doses |
| Pediatric Dose | Atropine solution (0.5%): 1-2 gtt into eye bid/tid Ointment: Not established Homatropine solution (2%): 1 gtt immediately before procedure; repeat in 10 min prn |
| Contraindications | Documented hypersensitivity; thyrotoxicosis; narrow-angle glaucoma; tachycardia |
| Interactions | Coadministration with other anticholinergics have additive effects; pharmacologic effects of atenolol and digoxin may increase; antipsychotic effects of phenothiazines may decrease; tricyclic antidepressants with anticholinergic activity may increase effects |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in Down syndrome and/or brain damage to prevent hyperreactive response; caution in coronary heart disease, tachycardia, congestive heart failure, cardiac arrhythmias, hypertension, peritonitis, ulcerative colitis, hepatic disease, and hiatal hernia with reflux esophagitis; in prostatic hypertrophy, prostatism can have dysuria and may require catheterization; caution in elderly patients who may have increased IOP; toxic anticholinergic systemic adverse effects can occur but rare when used sparingly; adverse effects more common in children, especially infants, than adults |
Topical anesthetics are used for analgesia to facilitate an adequate examination. These agents should never be prescribed for home use because they can cause secondary keratitis, compromise healing of the epithelial wound, and block protective corneal reflexes and sensation.
| Drug Name | Tetracaine HCl 0.5% (Pontocaine) |
|---|---|
| Description | Local anesthetic; blocks initiation and conduction of nerve impulses by decreasing sodium permeability neuronal membrane, inhibiting depolarization and blocking impulse conduction. Onset of action in 1 min; anesthetic effect up to 15-20 min. Stings considerably on application. Solution and ointment. |
| Adult Dose | Solution: 1-2 gtt Ointment: Apply 0.5-inch ribbon into conjunctival fornix |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Antagonizes effect of sulfonamides and aminosalicylic acid |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in cardiac disease and hyperthyroidism; may delay wound healing |
| Drug Name | Proparacaine 0.5% (Ophthaine) |
|---|---|
| Description | Least irritating of topical anesthetics. Prevents initiation and transmission of impulse at nerve cell membrane by stabilizing it and decreasing ion permeability. Onset of action in 20 sec; anesthetic effect up to 10-15 min. |
| Adult Dose | 1-2 gtt of 0.5% solution q5-10min for 5-7 doses |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; prolonged use |
| Interactions | Increases effects of phenylephrine and tropicamide |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in cardiac disease or hyperthyroidism and abnormal or reduced levels of plasma esterases |
Some ophthalmologists are advocating the use of diclofenac (Voltaren) or ketorolac (Acular) drops with a disposable soft contact lens in addition to antibiotic drops. This therapy may be an effective alternative to patching, as it allows the patient to maintain binocular vision during treatment and reduces inflammation. Patients with all but the most minor abrasions usually require a strong oral narcotic analgesic.
| Drug Name | Diclofenac (Voltaren); Ketorolac tromethamine 0.5% (Acular) |
|---|---|
| Description | Inhibit prostaglandin synthesis by decreasing cyclooxygenase activity, decreasing formation of prostaglandin precursors. |
| Adult Dose | 1 gtt into affected eye qid, maximum of 2 wk |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Ketorolac is pregnancy category C; corneal thinning may occur; perform ophthalmologic studies in patients with eye complaints during therapy; discontinue if changes (eg, blurred or diminished vision, corneal deposits, retinal disturbances, scotomata, changes in color vision, macula degeneration) noted |
| Drug Name | Hydrocodone bitartrate and acetaminophen (Vicodin ES); Oxycodone and acetaminophen (Percocet, Roxicet, Roxilox, Tylox) |
|---|---|
| Description | Drug combinations for relief of moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h or prn |
| Pediatric Dose | Hydrocodone bitartrate and acetaminophen: <12 years: 10-15 mg/kg/dose PO acetaminophen q4-6h prn; not to exceed 2.6 g/d acetaminophen or 5 mg hydrocodone bitartrate/dose >12 years: 750 mg PO acetaminophen q4h; not to exceed 5 doses/d acetaminophen or 10 mg hydrocodone bitartrate/dose Oxycodone and acetaminophen: 0.05-0.15 mg/kg/dose PO q4-6h or prn based on oxycodone dose; not to exceed 5 mg oxycodone/dose |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Tabs contain metabisulfite that may cause hypersensitivity; caution in patients dependent on opiates (substitution may result in acute opiate-withdrawal symptoms); caution in severe renal or hepatic dysfunction; duration of action may increase in elderly; be aware of total daily dose of acetaminophen (do not exceed 4000 mg/d), as higher doses may cause liver toxicity |
| Media file 1: This corneal abrasion appears as a yellow-green area when stained with fluorescein and viewed with a blue light. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Corneal abrasion. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Corneal abrasion. | |
![]() | View Full Size Image | Media type: Photo |